Dermorphin: Molecular Structure

Molecular Structure and Properties#

Dermorphin is a heptapeptide consisting of seven amino acid residues with the sequence Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 and a molecular weight of approximately 803.9 Da. The molecular formula is C40H50N6O9. The peptide is distinguished by two unusual structural features: the presence of a D-alanine residue at position 2 and C-terminal amidation of the serine residue.

Amino Acid Sequence Analysis#

The primary structure of dermorphin can be divided into functionally distinct domains. The N-terminal tripeptide Tyr-D-Ala-Phe constitutes the "message domain" that is essential for opioid receptor recognition and binding. This sequence shares structural homology with the enkephalin message sequence (Tyr-Gly-Gly-Phe) but with critical modifications that enhance mu-opioid receptor selectivity. The replacement of glycine residues with D-alanine and phenylalanine introduces conformational constraints that favor mu-receptor binding.

The C-terminal tetrapeptide Gly-Tyr-Pro-Ser-NH2 forms the "address domain" that modulates receptor selectivity and determines the specific pharmacological profile. The proline residue at position 6 introduces a kink in the peptide backbone, and the C-terminal amidation eliminates the negative charge that would otherwise be present at physiological pH.

The D-alanine residue at position 2 is biosynthetically derived from L-alanine through post-translational enzymatic isomerization. This D-configuration is critical for the peptide's biological activity, as replacement with L-alanine dramatically reduces mu-opioid receptor affinity and analgesic potency. The D-configuration also provides enhanced resistance to aminopeptidases, which preferentially cleave L-amino acid substrates.

Physicochemical Properties#

Dermorphin is a white to off-white powder in its lyophilized form. Key physicochemical properties include:

The peptide contains two tyrosine residues (positions 1 and 5) that contribute to UV absorbance at 280 nm, making spectrophotometric quantification feasible. The phenylalanine at position 3 also contributes to aromatic absorbance.

Conformational Analysis#

Nuclear magnetic resonance (NMR) and computational studies have revealed that dermorphin adopts a relatively compact conformation in solution, with the N-terminal tyrosine and the phenylalanine at position 3 positioned to interact with the ligand-binding pocket of the mu-opioid receptor. The D-alanine at position 2 constrains the phi and psi dihedral angles in a manner that is distinct from L-alanine, creating a backbone geometry that is optimal for MOR binding.

The proline at position 6 introduces a cis/trans isomerization equilibrium that may influence the bioactive conformation. Studies suggest that the trans-proline conformer is preferentially bound by the mu-opioid receptor, although both isomers may contribute to biological activity.

Pharmacokinetics#

Detailed pharmacokinetic data for dermorphin in standard animal models are limited compared to many synthetic peptides. Most pharmacological studies have employed central routes of administration (intracerebroventricular or intrathecal injection) to bypass the blood-brain barrier, which limits the relevance of systemic pharmacokinetic parameters.

Key pharmacokinetic observations include:

• Metabolic stability: The D-alanine residue provides significant protection against aminopeptidase-mediated degradation, extending the biological half-life compared to all-L-amino acid opioid peptides. However, the peptide remains susceptible to endopeptidases that cleave at internal peptide bonds.
• Blood-brain barrier penetration: Dermorphin shows limited ability to cross the blood-brain barrier following systemic administration, which has limited its development as a peripherally administered analgesic.
• Primary degradation pathway: Enzymatic cleavage occurs primarily at the Gly4-Tyr5 bond and at the N-terminal Tyr1-D-Ala2 bond (at slower rates due to D-configuration).
• Elimination: Metabolic fragments are expected to undergo standard amino acid catabolism and renal excretion.

Stability and Storage#

Dermorphin as a lyophilized powder is relatively stable when stored at -20 degrees C, protected from light and moisture. In aqueous solution, the peptide is stable at physiological pH for several hours but may undergo oxidation of tyrosine residues and hydrolysis of the C-terminal amide bond over longer periods. Solutions should be prepared fresh or stored at -80 degrees C in aliquots to avoid repeated freeze-thaw cycles.

The D-alanine residue provides inherent protection against enzymatic degradation compared to all-L peptides, but does not prevent chemical degradation pathways such as oxidation, deamidation, or hydrolysis under non-physiological conditions.

Structure-Activity Relationships#

Extensive structure-activity relationship (SAR) studies have been conducted on dermorphin, yielding important insights:

• Position 1 (Tyr): Essential for activity. Removal or substitution abolishes opioid receptor binding. The phenolic hydroxyl group is critical for hydrogen bonding with the receptor.
• Position 2 (D-Ala): D-configuration is required for high potency. L-Ala substitution reduces activity by 100-fold or more. Larger D-amino acids (D-Met, D-Arg) can modulate selectivity profiles.
• Position 3 (Phe): Important for receptor binding and selectivity. Para-substituted phenylalanine analogs have been used to develop affinity labels for opioid receptors.
• Position 4 (Gly): Provides backbone flexibility. Substitution with larger amino acids reduces activity.
• Position 5 (Tyr): Contributes to receptor binding but is less critical than Tyr1.
• Position 6 (Pro): Constrains peptide conformation; substitution alters pharmacological profile.
• Position 7 (Ser-NH2): C-terminal amidation enhances activity and metabolic stability.

These SAR findings have guided the development of numerous dermorphin analogs with tailored pharmacological properties, including compounds with enhanced selectivity, prolonged duration of action, and improved metabolic stability.

Related Reading#

• Dermorphin overview and research guide
• Peptides similar to Dermorphin
• Dermorphin research evidence